# Twist Bioscience Corp: financial statements, quarterly

TWST · Nasdaq · CIK 1581280 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Sep 30

Pages: [Overview](/companies/twst.md) · [Financials](/companies/twst/financials.md) · [Filings](/companies/twst/filings.md) · [Insiders](/companies/twst/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/twst/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [66.9 d](/filings/0001581280-25-000025.md) | [71.5](/filings/0001628280-25-003461.md) | [75.3](/filings/0001628280-25-022154.md) | [81.5](/filings/0001581280-25-000009.md) | [84.7 d](/filings/0001581280-25-000025.md) | [88.7](/filings/0001581280-26-000029.md) | [92.8](/filings/0001581280-26-000040.md) | [96.1](/filings/0001581280-26-000047.md) | [99.0 d](/filings/0001581280-25-000025.md) | [104](/filings/0001581280-26-000029.md) | [111](/filings/0001581280-26-000040.md) | [118](/filings/0001581280-26-000047.md) |
| Cost of revenue | $m | [42.4 d](/filings/0001581280-25-000025.md) | [42.5](/filings/0001628280-25-003461.md) | [44.4](/filings/0001628280-25-022154.md) | [46.2](/filings/0001581280-25-000009.md) | [46.5 d](/filings/0001581280-25-000025.md) | [45.9](/filings/0001581280-26-000029.md) | [46.8](/filings/0001581280-26-000040.md) | [44.8](/filings/0001581280-26-000047.md) | [48.2 d](/filings/0001581280-25-000025.md) | [49.7](/filings/0001581280-26-000029.md) | [53.6](/filings/0001581280-26-000040.md) | [55.9](/filings/0001581280-26-000047.md) |
| Research and development | $m | [23.7 d](/filings/0001581280-25-000025.md) | [23.1](/filings/0001628280-25-003461.md) | [24.1](/filings/0001628280-25-022154.md) | [22.5](/filings/0001581280-25-000009.md) | [21.1 d](/filings/0001581280-25-000025.md) | [21.3](/filings/0001581280-26-000029.md) | [23.9](/filings/0001581280-26-000040.md) | [18.0](/filings/0001581280-26-000047.md) | [17.0 d](/filings/0001581280-25-000025.md) | [17.1](/filings/0001581280-26-000029.md) | [19.7](/filings/0001581280-26-000040.md) | [18.0](/filings/0001581280-26-000047.md) |
| Selling, general and administrative | $m | [47.4 d](/filings/0001581280-25-000025.md) | [52.8](/filings/0001628280-25-003461.md) | [55.6](/filings/0001628280-25-022154.md) | [56.8](/filings/0001581280-25-000009.md) | [53.1 d](/filings/0001581280-25-000025.md) | [56.2](/filings/0001581280-26-000029.md) | [63.7](/filings/0001581280-26-000040.md) | [63.4](/filings/0001581280-26-000047.md) | [63.8 d](/filings/0001581280-25-000025.md) | [69.7](/filings/0001581280-26-000029.md) | [76.1](/filings/0001581280-26-000040.md) | [80.7](/filings/0001581280-26-000047.md) |
| Operating income | $m | [(50.1) d](/filings/0001581280-25-000025.md) | [(47.0)](/filings/0001628280-25-003461.md) | [(48.9)](/filings/0001628280-25-022154.md) | [(88.9)](/filings/0001581280-25-000009.md) | [(36.0) d](/filings/0001581280-25-000025.md) | [(34.6)](/filings/0001581280-26-000029.md) | [(41.6)](/filings/0001581280-26-000040.md) | [(30.1)](/filings/0001581280-26-000047.md) | [(29.9) d](/filings/0001581280-25-000025.md) | [(32.9)](/filings/0001581280-26-000029.md) | [(45.9)](/filings/0001581280-26-000040.md) | [(36.3)](/filings/0001581280-26-000047.md) |
| Interest expense | $m | [0.0 d](/filings/0001628280-23-039767.md) | [0.0](/filings/0001628280-24-003051.md) | [0.0](/filings/0001628280-24-020014.md) | [0.0](/filings/0001628280-24-034434.md) | [0.0 d](/filings/0001628280-24-048262.md) | [0.0](/filings/0001628280-25-003461.md) | [0.1](/filings/0001628280-25-022154.md) | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [(0.2) d](/filings/0001581280-25-000025.md) | [0.1](/filings/0001628280-25-003461.md) | [0.3](/filings/0001628280-25-022154.md) | [0.2](/filings/0001581280-25-000009.md) | [(0.1) d](/filings/0001581280-25-000025.md) | [0.1](/filings/0001581280-26-000029.md) | [0.2](/filings/0001581280-26-000040.md) | [0.2](/filings/0001581280-26-000047.md) | [0.3 d](/filings/0001581280-25-000025.md) | [0.3](/filings/0001581280-26-000029.md) | [0.0](/filings/0001581280-26-000040.md) | [0.3](/filings/0001581280-26-000047.md) |
| Net income | $m | [(46.2) d](/filings/0001581280-25-000025.md) | [(43.0)](/filings/0001628280-25-003461.md) | [(45.5)](/filings/0001628280-25-022154.md) | [(85.6)](/filings/0001581280-25-000009.md) | [(34.7) d](/filings/0001581280-25-000025.md) | [(31.6)](/filings/0001581280-26-000029.md) | [(39.3)](/filings/0001581280-26-000040.md) | [20.4](/filings/0001581280-26-000047.md) | [(27.1) d](/filings/0001581280-25-000025.md) | [(30.5)](/filings/0001581280-26-000029.md) | [(44.0)](/filings/0001581280-26-000040.md) | [(35.1)](/filings/0001581280-26-000047.md) |
| Diluted EPS | $ per share | not reported | [(0.75)](/filings/0001628280-25-003461.md) | [(0.79)](/filings/0001628280-25-022154.md) | [(1.47)](/filings/0001581280-25-000009.md) | not reported | [(0.53)](/filings/0001581280-26-000029.md) | [(0.66)](/filings/0001581280-26-000040.md) | [0.33](/filings/0001581280-26-000047.md) | not reported | [(0.50)](/filings/0001581280-26-000029.md) | [(0.71)](/filings/0001581280-26-000040.md) | [(0.56)](/filings/0001581280-26-000047.md) |
| Basic EPS | $ per share | not reported | [(0.75)](/filings/0001628280-25-003461.md) | [(0.79)](/filings/0001628280-25-022154.md) | [(1.47)](/filings/0001581280-25-000009.md) | not reported | [(0.53)](/filings/0001581280-26-000029.md) | [(0.66)](/filings/0001581280-26-000040.md) | [0.34](/filings/0001581280-26-000047.md) | not reported | [(0.50)](/filings/0001581280-26-000029.md) | [(0.71)](/filings/0001581280-26-000040.md) | [(0.56)](/filings/0001581280-26-000047.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [286](/filings/0001628280-24-048262.md) | [266](/filings/0001628280-24-003051.md) | [243](/filings/0001628280-24-020014.md) | [239](/filings/0001628280-24-034434.md) | [226](/filings/0001581280-25-000025.md) | [221](/filings/0001628280-25-003461.md) | [210](/filings/0001628280-25-022154.md) | [201](/filings/0001581280-25-000009.md) | [183](/filings/0001581280-26-000047.md) | [149](/filings/0001581280-26-000029.md) | [123](/filings/0001581280-26-000040.md) | [117](/filings/0001581280-26-000047.md) |
| Current assets | $m | [424](/filings/0001628280-24-048262.md) | [390](/filings/0001628280-24-003051.md) | [372](/filings/0001628280-24-020014.md) | [362](/filings/0001628280-24-034434.md) | [347](/filings/0001581280-25-000025.md) | [345](/filings/0001628280-25-003461.md) | [338](/filings/0001628280-25-022154.md) | [340](/filings/0001581280-25-000009.md) | [333](/filings/0001581280-26-000047.md) | [304](/filings/0001581280-26-000029.md) | [323](/filings/0001581280-26-000040.md) | [321](/filings/0001581280-26-000047.md) |
| Total assets | $m | [776](/filings/0001628280-24-048262.md) | [733](/filings/0001628280-24-003051.md) | [703](/filings/0001628280-24-020014.md) | [638](/filings/0001628280-24-034434.md) | [614](/filings/0001581280-25-000025.md) | [609](/filings/0001628280-25-003461.md) | [596](/filings/0001628280-25-022154.md) | [644](/filings/0001581280-25-000009.md) | [642](/filings/0001581280-26-000047.md) | [638](/filings/0001581280-26-000029.md) | [676](/filings/0001581280-26-000040.md) | [672](/filings/0001581280-26-000047.md) |
| Current liabilities | $m | [73.3](/filings/0001628280-24-048262.md) | [65.2](/filings/0001628280-24-003051.md) | [67.5](/filings/0001628280-24-020014.md) | [73.8](/filings/0001628280-24-034434.md) | [71.0](/filings/0001581280-25-000025.md) | [69.6](/filings/0001628280-25-003461.md) | [75.0](/filings/0001628280-25-022154.md) | [87.1](/filings/0001581280-25-000009.md) | [91.4](/filings/0001581280-26-000047.md) | [80.4](/filings/0001581280-26-000029.md) | [120](/filings/0001581280-26-000040.md) | [120](/filings/0001581280-26-000047.md) |
| Total liabilities | $m | [153](/filings/0001628280-24-048262.md) | [143](/filings/0001628280-24-003051.md) | [143](/filings/0001628280-24-020014.md) | [147](/filings/0001628280-24-034434.md) | [142](/filings/0001581280-25-000025.md) | [153](/filings/0001628280-25-003461.md) | [156](/filings/0001628280-25-022154.md) | [165](/filings/0001581280-25-000009.md) | [169](/filings/0001581280-26-000047.md) | [182](/filings/0001581280-26-000029.md) | [221](/filings/0001581280-26-000040.md) | [227](/filings/0001581280-26-000047.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [623](/filings/0001581280-25-000025.md) | [590](/filings/0001628280-25-022154.md) | [560](/filings/0001581280-25-000009.md) | [491](/filings/0001581280-25-000009.md) | [473](/filings/0001581280-26-000047.md) | [456](/filings/0001581280-26-000040.md) | [440](/filings/0001581280-26-000047.md) | [478](/filings/0001581280-26-000047.md) | [473](/filings/0001581280-26-000047.md) | [456](/filings/0001581280-26-000040.md) | [455](/filings/0001581280-26-000047.md) | [446](/filings/0001581280-26-000047.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(20.7) d](/filings/0001581280-25-000025.md) | [(23.0)](/filings/0001628280-25-003461.md) | [(19.4) d](/filings/0001628280-25-022154.md) | [(6.4) d](/filings/0001581280-25-000009.md) | [(15.3) d](/filings/0001581280-25-000025.md) | [(21.4)](/filings/0001581280-26-000029.md) | [(13.0) d](/filings/0001581280-26-000040.md) | [(1.4) d](/filings/0001581280-26-000047.md) | [(11.8) d](/filings/0001581280-25-000025.md) | [(24.8)](/filings/0001581280-26-000029.md) | [(17.6) d](/filings/0001581280-26-000040.md) | [1.1 d](/filings/0001581280-26-000047.md) |
| Capital expenditure | $m | [2.4 d](/filings/0001581280-25-000025.md) | [1.5](/filings/0001628280-25-003461.md) | [0.6 d](/filings/0001628280-25-022154.md) | [1.0 d](/filings/0001581280-25-000009.md) | [2.0 d](/filings/0001581280-25-000025.md) | [2.3](/filings/0001581280-26-000029.md) | [4.1 d](/filings/0001581280-26-000040.md) | [9.2 d](/filings/0001581280-26-000047.md) | [12.4 d](/filings/0001581280-25-000025.md) | [10.0](/filings/0001581280-26-000029.md) | [7.9 d](/filings/0001581280-26-000040.md) | [9.8 d](/filings/0001581280-26-000047.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2023 (2022-12-31) | Q2 FY2023 (2023-03-31) | Q3 FY2023 (2023-06-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [56.4](/filings/0001628280-24-003051.md) | [56.8](/filings/0001628280-24-020014.md) | [57.0](/filings/0001628280-24-034434.md) | [57.5](/filings/0001628280-25-003461.md) | [57.8](/filings/0001628280-25-022154.md) | [58.1](/filings/0001581280-25-000009.md) | [59.2](/filings/0001581280-26-000029.md) | [59.6](/filings/0001581280-26-000040.md) | [61.2](/filings/0001581280-26-000047.md) | [61.1](/filings/0001581280-26-000029.md) | [61.7](/filings/0001581280-26-000040.md) | [62.4](/filings/0001581280-26-000047.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 62,707,424 at 2026-07-29, from the cover of the [10-Q filed 2026-08-03](/filings/0001581280-26-000047.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:43 ET. No prices; not investment advice.